Cargando…
A Case of Relapsed Primary Central Nervous System Lymphoma Treated with CD19-directed Chimeric Antigen Receptor T Cell Therapy
Although high-dose methotrexate (HD-MTX) is the standard therapy for primary central nervous system lymphoma (PCNSL), the prognosis remains poor. Because 90% of PCNSL is diffuse large B-cell lymphoma (DLBCL), chimeric antigen receptor (CAR)-T cell therapy is expected to be beneficial. However, there...
Autores principales: | MIZUTA, Ryo, OTANI, Yoshihiro, FUJII, Kentaro, UNEDA, Atsuhito, ISHIDA, Joji, TANAKA, Takehiro, IKEGAWA, Shuntaro, FUJII, Nobuharu, MAEDA, Yoshinobu, DATE, Isao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japan Neurosurgical Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512489/ https://www.ncbi.nlm.nih.gov/pubmed/36238605 http://dx.doi.org/10.2176/jns-nmc.2022-0134 |
Ejemplares similares
-
IDH-mutant Astrocytoma Arising in the Brainstem with Symptom Improvement by Foramen Magnum Decompression: A Case Report
por: NAGASE, Takayuki, et al.
Publicado: (2023) -
Differentiated glioblastoma cells accelerate tumor progression by shaping the tumor microenvironment via CCN1-mediated macrophage infiltration
por: Uneda, Atsuhito, et al.
Publicado: (2021) -
Spinal Cord Diffuse Midline Glioma, H3K27M- mutant Effectively Treated with Bevacizumab: A Report of Two Cases
por: YABUNO, Satoru, et al.
Publicado: (2021) -
PIK3R1Met326Ile germline mutation correlates with cysteine-rich protein 61 expression and poor prognosis in glioblastoma
por: Otani, Yoshihiro, et al.
Publicado: (2017) -
Annexin A2–STAT3–Oncostatin M receptor axis drives phenotypic and mesenchymal changes in glioblastoma
por: Matsumoto, Yuji, et al.
Publicado: (2020)